Your shopping cart is currently empty

Inosine-5'-diphosphoric acid disodium salt, as a decoy substrate for NM23-H2, exhibits excellent binding ability at the GDP-binding site of NM23-H2 with a dissociation constant (KD) of 5.0 μM. It can inhibit c-MYC transcription by disrupting the interaction between NM23-H2-Pu27-GQ, thereby inducing apoptosis and G2/M cell cycle arrest without affecting the kinase activity mediated by NM23-H2. Inosine-5'-diphosphoric acid disodium salt also possesses anti-hypoxic, antihypertensive, and antiarrhythmic activities, protects organisms from γ-radiation damage, and can be used in research on cancers such as Burkitt lymphoma and cardiovascular diseases.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 g | $29 | - | In Stock |
| Description | Inosine-5'-diphosphoric acid disodium salt, as a decoy substrate for NM23-H2, exhibits excellent binding ability at the GDP-binding site of NM23-H2 with a dissociation constant (KD) of 5.0 μM. It can inhibit c-MYC transcription by disrupting the interaction between NM23-H2-Pu27-GQ, thereby inducing apoptosis and G2/M cell cycle arrest without affecting the kinase activity mediated by NM23-H2. Inosine-5'-diphosphoric acid disodium salt also possesses anti-hypoxic, antihypertensive, and antiarrhythmic activities, protects organisms from γ-radiation damage, and can be used in research on cancers such as Burkitt lymphoma and cardiovascular diseases. |
| Targets&IC50 | NM23-H2:5.0 μM (Kd) |
| In vitro | Inosine-5'-diphosphoric acid disodium salt can serve as a decoy substrate for NM23‑H2, binding to its GDP-binding site with a dissociation constant (Kd) of 5.0 μM. It can interfere with the interaction between NM23‑H2 and the c‑MYC G-quadruplex (Pu27‑GQ), and enhance the inhibitory effect of Pu27‑GQ ligands on c‑MYC transcription, thereby inducing cell apoptosis and G2/M phase cycle arrest without affecting the intrinsic kinase activity of NM23‑H2. Inosine‑5'‑diphosphate disodium also exhibits biological activities such as anti-hypoxia, anti-hyperthermia and anti-arrhythmia, can reduce the damage to the body caused by γ-rays, and has important application value in the related research of malignant tumors such as Burkitt's lymphoma and cardiovascular diseases [1][2][3]. |
| Synonyms | Inosine-5'-diphosphoric acid disodium, Inosine-5'-diphosphate disodium, IDP disodium |
| Molecular Weight | 472.15 |
| Formula | C10H12N4Na2O11P2 |
| Cas No. | 54735-61-4 |
| Smiles | O[C@H]1[C@H](N2C3=C(N=C2)C(N=CN3)=O)O[C@H](COP(OP([O-])([O-])=O)(O)=O)[C@H]1O.[Na+].[Na+] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 140 mg/mL (296.52 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.